Ignite Creation Date:
2024-10-26 @ 3:35 PM
Last Modification Date:
2024-10-26 @ 3:35 PM
Study NCT ID:
NCT06503042
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-07-09
Brief Title:
A Study to Prospectively Validate Blood Markers Associated With Differences in Efficacy of Neoadjuvant Therapy for NSCLC
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Study to Prospectively Validate Blood Markers Associated With Differences in Efficacy of Neoadjuvant Therapy for Non-small Cell Lung Cancer
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study utilized a prospective cohort design It is proposed to analyze the serum of NSCLC patients treated with chemotherapy combined with immunotherapy and chemotherapy alone starting from liquid biopsy technique and combining with proteomic methods By comparing the differences in serum proteins between the two groups of patients before treatment we will validate the targets related to efficacy and AE events identified in a previous retrospective study further explore their associations with patients clinical outcomes and AE events and establish a clinical prediction model to guide and improve the current treatment of NSCLC
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None